Skip to main content

Advertisement

Table 5 Serious adverse events reported during second-line therapy

From: Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry

  Everolimus (n = 520) Sorafenib (n = 240) Sunitinib (n = 228)
Serious adverse events, n (%) 24 (4.6) 31 (12.9) 29 (12.7)
Types of serious adverse eventsa, n (%)
 Gastrointestinal 3 (0.6) 8 (3.3) 8 (3.5)
 Haematologic 2 (0.4) 3 (1.3) 8 (3.5)
 Cardiovascular 1 (0.2) 3 (1.3) 3 (1.3)
 Metabolic 2 (0.4) 6 (2.5) 1 (0.4)
 Dermatologic 2 (0.4) 9 (3.8) 1 (0.4)
 Respiratory 8 (1.5) 0 (0.0) 2 (0.9)
 Fatigue 2 (0.4) 2 (0.8) 1 (0.4)
 Other 5 (1.0) 6 (2.5) 5 (2.2)
  1. aOne patient can have more serious adverse events